Shares of Aphria (TSX:APHA)(NYSE:APHA) have made a strong comeback recently. The stock has gained 25% since the start of August 2019. While Aphria shares have fallen 60% since September last year, they are up by an impressive 1,050% since its IPO in December 2014. Most cannabis stocks have generated significant returns in the last five years, despite a steep pullback…
Read More
It’s almost unbelievable how much marijuana stocks have come down. It seemed times of trouble were over with the new year, as many pot stocks managed to rebound to where they were during the summer of 2018. Some even hit all-time highs. But that all changed around April, when pot stocks, again, slumped. Since then, it’s been a struggle for…
Read More
According to Brad Moore, CEO of Global Cannabis Application Corp (GCAC), the world view of cannabis is evolving beyond the perception of marijuana as it has been perceived (a recreational solution delivered via a joint, reefer, fatty, pot, ) to what it is becoming known as: a product with medical implications that are hard to ignore.It has governments, growers, and…
Read More
Pressure Biosciences, Inc. (OTCQB: PBIO) operates within the research, development, and sale of pressure-based solutions geared towards the life sciences industry. Shares of the biosciences company are jumping 38.02%, through early trading on Thursday, August 22, 2019. Over the past month, Pressure BioSciences has seen average daily volume of 8,330 shares. However, volume of 36,029 shares or dollar volume of…
Read More
Aphria Inc (TSX:APHA)(NYSE:APHA) has been a surprise winner in an otherwise terrible summer for marijuana stocks, rising more than 20% after a Q4 earnings beat. The company’s financial results and its rising share price distinguish it from other marijuana stocks, which have been getting hit thanks to a combination of negative earnings and increased regulatory scrutiny. In Q4, Aphria posted results…
Read More
Last week was a rough one for Canopy Growth Corp (TSX:WEED)(NYSE:CGC). The stock had already been struggling in recent months and after the company released its first-quarter results, the stock fell even further, falling below $40 a share for the first time since January. At over $37 to finish the week, Canopy Growth is right around its 52-week low and there’s the…
Read More
Cannabis investors have had a rough ride in the last 12 months. Several stocks lost significant value due to regulatory issues and missing analyst target estimates. Cannabis stocks were overvalued and expensive. Shares of Cronos Group (TSX:CRON)(NASDAQ:CRON) have fallen 46% since March 2019. Despite the recent pullback, the stock has returned a mind-blowing 1,825% since its IPO back in December…
Read More
The cannabis market has experienced a seismic shift over the past few years. Sales have grown at an exponential rate, and many of the top firms in the sector have seen their share prices skyrocket. Thankfully, it isn’t too late for those looking to profit from this rare opportunity. The cannabis industry is projected to keep growing, both in North…
Read More
After Aphria announced its financial earnings for the 2019 fiscal year this month, you might have been curious about the performance of CannTrust (TSX:TRST)(NYSE:CTST). Unfortunately, you will be bitterly disappointed by the company after it started to face problems with regulators and its stock plummeted. What happened with CannTrust? The dominoes began to fall when CannTrust applied for a management…
Read More
Last week was not a good one for Canopy Growth Corporation (TSX:WEED)(NYSE:CGC). After some of its competitors announced solid earnings — including a few who told investors they were profitable — Canopy Growth disappointed the market when it announced adjusted EBITDA of negative $92 million. That came on net revenue of just over $90 million, which was lower than analysts…
Read More